| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H11NO7P2 |
| Molecular Weight | 283.1123 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
InChI
InChIKey=IIDJRNMFWXDHID-UHFFFAOYSA-N
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
| Molecular Formula | C7H11NO7P2 |
| Molecular Weight | 283.1123 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month, 150 mg once-a-month.
Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week.
Men with Osteoporosis: 35 mg once-a-week.
Glucocorticoid-Induced Osteoporosis: 5 mg daily.
Paget’s Disease: 30 mg daily for 2 month.
Route of Administration:
Oral
